1.Date of the board of directors resolution for the change:2022/05/11
2.Effective registration date of the original plan:2007/12/04
3.Resolution date of additional issuance:NA
4.Major change Reason for the change:
(1)MB-6 colorectal cancer adjuvant drug (hereinafter referred to as MB-6)
   was approved by the Department of Health of the Executive Yuan to proceed
   with a Phase III clinical trail in January 2013. Starting from the fourth
   quarter of 2013, the Phase III clinical trail has been initiated in 6
   medical centers in Taiwan. Considering the new requirements by
   international regulations on the natural medicines formulated with
   multiple APIs with regards to the Angiospermae origin, planting, detailed
   fingerprint chromatogram, the risk of MB-6 in NDA submission is likely
   increased in the future. After assessment, we decided to adjust the
   development of colorectal cancer adjuvant drugs. The current priority is
   advancing the exploratory trial on the approved drug, MS20 in combination
   with PD1 antibody or expand the indication of MS20 to adjuvant therapy to
   the colorectal cancer immunotherapy to replace the development plan of
   MB-6 in colorectal cancer, so that we can accelerate the process for new
   drugs to enter the market.
(2)Company's funds can support the subsequent RD expenditure,but considering
   the long development timeline of this project, we plan to strengthen
   working capital by altering the plan and using the remaining funds of
   NT$31,293,000 under the cash captial increase plpan in 2007 for MB-6
   adjuvant drug in colorectal cancer. This is to ensure that the funds can
   be used and allocated more effectively.
5.Content of each and every successive previously changed
plan for raising of funds before and after change:

Original capital utilization plan：

Project                 Scheduled completion date      Toatal required funds
------------------------------------------------------------------------------------------------
New drug development    2012Q4                         NT$846,000,000
================================================================================================

The first change of capital utilization plan：

Project                 Scheduled completion date      Toatal required funds
------------------------------------------------------------------------------------------------
New drug development    2012Q4                         NT$579,000,000
Invest a new split up
  company               2008Q2                         NT$171,000,000
------------------------------------------------------------------------------------------------
Total amount                                           NT$750,000,000
================================================================================================

The second change of capital utilization plan：

Project                 Scheduled completion date      Toatal required funds
------------------------------------------------------------------------------------------------
New drug development    2017Q4                         NT$297,562,000
Invest a new split up
  company               2008Q2                         NT$162,094,000
Strengthen working
  capital               2014Q1                         NT$290,344,000
------------------------------------------------------------------------------------------------
Total amount                                           NT$750,000,000
================================================================================================

The third change of capital utilization plan：

Project                 Scheduled completion date      Toatal required funds
------------------------------------------------------------------------------------------------
New drug development    2017Q4                         NT$281,183,000
Invest a new split up
  company               2008Q2                         NT$162,094,000
Strengthen working
  capital               2015Q1                         NT$306,723,000
------------------------------------------------------------------------------------------------
Total amount                                           NT$750,000,000
================================================================================================

The fourth change of capital utilization plan：

Project                 Scheduled completion date      Toatal required funds
------------------------------------------------------------------------------------------------
New drug development    2017Q4                         NT$249,890,000
Invest a new split up
  company               2008Q2                         NT$162,094,000
Strengthen working
  capital               2022Q2                         NT$338,016,000
-------------------------------------------------------------------------------------------------
Total amount                                           NT$750,000,000
=================================================================================================
6.Projected timetable for execution:2022Q2
7.Projected completion date:2022Q2
8.Projected possible benefits:
(1)New drug development：
   MS-20 Microbio ”Chemo Young” obtained the first oral cancer adjuvant drug
   certificate in Taiwan in December 2011, and went on sale in the second
   quarter of 2012. Starting from 2012 to the first quarter of 2022 ”Chemo
   Young” sales revenue is in total of NT$286,585,000. The difference from
   the expected benefit of NT$656,332,000 is mainly due to the fact that the
   performance of the hospital channel requires all links' cooperation and
   the medicines purchase needs to go through the administrative procedures
   to get the approval from doctors. Therefore, it takes longer than other
   channels and the expected benefits haven't been achieved yet, but the
   annual revenue has shown steady growth with the marketing team's efforts.
(2)Invest a new split up company：
   Reinvestment and division of a new company—the implementation progress
   of the fund implantation of Oneness Biotech Co., Ltd. has been completed
   in the third quarter of 2008. The Company disposed of part of Oneness
   Biotech’s equity in 2008, and generated the disposal benefit in total
   amount of NT$150,146,000. According to Oneness Biotech's 2010~2013 profit
   and loss after-tax reviewed and certified by the accountants, the
   reinvestment benefit amounting to NT$60,506,000 was recognized. So the
   estimated benefit of the plan of reinvestment and division of a new
   company has been achieved.
(3)Strengthen working capital：
   We didn't change the expected benefit since the replenishment of working
   capital has been completed before this change of the plan. This time, the
   remaining capital of NT$31,293,000 from MB-6 project was transferred to
   replenishment of working capital. Calculated based on the average
   borrowing interest rate at the time of the plan change, it can save
   NT$491,000 in interest every year.
9.Difference from original projected benefits:
This change of the plan will transfer the unspent funds of the MB-6 project
into strengthening working capital. The expected benefit is saving about
NT$491,000 in interest every year. There is a difference from the sales
revenue of NT$113,400,000 expected to be generated by the original MB-6
project.
10.Effect of the current change on shareholder equity:
This change of the plan is mainly transfer the unspent funds of the MB-6
project into strengthening working capital. It can benefit shareholders'
rights and interests by reducing the risk of new drugs reserch and
development, by improving the flexibility of capital allocation, and by
saving interest expenses.
11.Abstract of the original lead underwriter's appraisal opinion:
This change of the plan does not reach 20% of the total amount of the
fundraising plan. It is not a change in the fundraising plan mentioned
in the matters needing attention for the change of the public offering
company's cash capital increase or the plan to issue corporate bonds.
Therefore, there is no need to contact the original sponsoring underwriter
to issue an evaluation opinion.
12.Any other matters that need to be specified:None